Publications by authors named "Shu-Wu Wang"
LSD1 (histone lysine-specific demethylase 1) has been gradually disclosed to act as an immunomodulator to enhance antitumor immune response. Despite the identification of numerous potent LSD1 inhibitors, there remains a lack of LSD1 inhibitors approved for marketing. Novel LSD1 inhibitors with different mechanisms are therefore needed.
View Article and Find Full Text PDFArticle Synopsis
- Lysine specific demethylase 1 (LSD1) is a key transcriptional modulator that is commonly overexpressed in various cancers, disrupting normal gene expression networks.
- Over 10 LSD1 inhibitors, including eight irreversible and two reversible types, have been developed and some have reached clinical trials, often showing better results when used with other treatments.
- The review discusses the potential of combining LSD1 inhibitors with other cancer therapies, highlights new multitarget inhibitors, and addresses challenges and future research directions in developing LSD1-targeted cancer treatments.*
With the booming development of precision medicine, molecular targeted therapy has been widely used in clinical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of traditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance.
View Article and Find Full Text PDF